Abstract
Pramipexole (PPX) is a D2/D3 receptor agonist that has been shown to be effective in the treatment of depression. Serotonin (5-HT), norepinephrine (NE) and dopamine (DA) systems are known to be involved in the pathophysiology and treatment of depression. Due to reciprocal interactions between these neuronal systems, drugs selectively targeting one system-specific receptor can indirectly modify the firing activity of neurons that contribute to firing patterns in systems that operate via different neurotransmitters. It was thus hypothesized that PPX would alter the firing rate of DA, NE and 5-HT neurons. To test this hypothesis, electrophysiological experiments were carried out in anesthetized rats. Subcutaneously implanted osmotic minipumps delivered PPX at a dose of 1 mg/kg per day for 2 or 14 days. After a 2-day treatment with PPX the spontaneous neuronal firing of DA neurons was decreased by 40%, NE neuronal firing by 33% and the firing rate of 5-HT neurons remained unaltered. After 14 days of PPX treatment, the firing rate of DA had recovered as well as that of NE, whereas the firing rate of 5-HT neurons was increased by 38%. It was also observed that sustained PPX administration produced desensitization of D2/D3 and 5-HT1A cell body autoreceptors, as well as a decrease in sensitivity of α2-adrenergic cell body autoreceptors. These adaptive changes are implicated in long-term firing rate adaptations of DA, NE and 5-HT neurons after prolonged PPX administration. In conclusion, the therapeutic action of PPX in depression might be attributed to increased DA and 5-HT neurotransmission.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Aghajanian GK, Vandermaelen CP (1982a). Intracellular recording in vivo from serotonergic neurons in the rat dorsal raphe nucleus: methodological considerations. J Histochem Cytochem 30: 813–814.
Aghajanian GK, Vandermaelen CP (1982b). Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure. J Neurosci 2: 1786–1792.
Aman TK, Shen RY, Haj-Dahmane S (2007). D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther 320: 376–385.
Anisman H, Remington G, Sklar LS (1979). Effect of inescapable shock on subsequent escape performance: catecholaminergic and cholinergic mediation of response initiation and maintenance. Psychopharmacology (Berl) 61: 107–124.
Blier P (2001). Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 26 (Suppl): S3–S10.
Blier P, De Montigny C (1983). Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3: 1270–1278.
Blier P, de Montigny C, Tardif D (1987). Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1A receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse 1: 225–232.
Brocco M, Dekeyne A, Papp M, Millan MJ (2006). Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 17: 559–572.
Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A et al (2004). Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 20: 131–138.
Chaput Y, Blier P, de Montigny C (1986). In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 6: 2796–2801.
Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000). Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety 11: 58–65.
Dremencov E, El Mansari M, Blier P (2007). Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61: 671–678.
Dremencov E, Gispan-Herman I, Rosenstein M, Mendelman A, Overstreet DH, Zohar J et al (2004). The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 28: 141–147.
Dunlop BW, Nemeroff CB (2007). The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64: 327–337.
Ennis M, Aston-Jones G (1988). Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brain. J Neurosci 8: 3644–3657.
Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 7: 177–185.
Ferre S, Artigas F (1993). Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem 61: 772–775.
Gartside SE, Hajos-Korcsok E, Bagdy E, Harsing Jr LG, Sharp T, Hajos M (2000). Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 98: 295–300.
Goldberg JF, Burdick KE, Endick CJ (2004). Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161: 564–566.
Gonon FG (1988). Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24: 19–28.
Grace AA, Bunney BS (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons. Neuroscience 10: 301–348.
Grace AA, Bunney BS (1984). The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4: 2877–2890.
Guiard BP, El Mansari M, Merali Z, Blier P (2008a). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11: 625–639.
Guiard BP, El Mansari M, Blier P (2008b). Crosstalk between dopaminergic and noradrenergic systems in the rat locus coeruleus, ventral tegmental area, and dorsal hippocampus (submitted).
Guttman M, Jaskolka J (2001). The use of pramipexole in Parkinson's disease: are its actions D(3) mediated. Parkinsonism Relat Disord 7: 231–234.
Haddjeri N, Blier P (2000). Effects of sustained (+/−)pindolol administration on serotonin neurotransmission in rats. J Psychiatry Neurosci 25: 378–388.
Haddjeri N, Blier P, de Montigny C (1998a). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18: 10150–10156.
Haddjeri N, De Montigny C, Curet O, Blier P (1998b). Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. Eur J Pharmacol 343: 179–192.
Haj-Dahmane S (2001). D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci 14: 125–134.
Hajós M, Gartside SE, Villa AE, Sharp T (1995). Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience 69: 189–197.
Hajós M, Sharp T (1996). Burst-firing activity of presumed 5-HT neurones of the rat dorsal raphe nucleus: electrophysiological analysis by antidromic stimulation. Brain Res 740: 162–168.
Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y et al (2000). Open pergolide treatment of tricyclic and heterocyclic depression. J Affect Disord 61: 127–132.
Jeziorski M, White FJ (1989). Dopamine agonists at repeated ‘autoreceptor-selective’ doses: effects upon the sensitivity of A10 dopamine autoreceptors. Synapse 4: 267–280.
Kreiss DS, Lucki I (1995). Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274: 866–876.
Lacroix D, Blier P, Curet O, de Montigny C (1991). Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain. J Pharmacol Exp Ther 257: 1081–1090.
Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR et al (2002). Pramipexole in treatment-resistant depressive illness: evidence in support of the cathecholamine hypothesis of mood disorders. Arch Gen Psychiatry 57: 787–793.
Levant B, Grigoriadis DE, DeSouza EB (1993). [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. J Pharmacol Exp Ther 264: 991–1001.
Maj J, Rogoz Z, Skuza G, Kolodziejczyk K (1997). Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 104: 525–533.
Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ (1990). Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. J Neurosci 10: 2587–2600.
Martin-Ruiz R, Ugedo L, Honrubia MA, Mengod G, Artigas F (2001). Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J Neurochem 77: 762–775.
Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM et al (2000b). S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 and L741, 626. J Pharmacol Exp Ther 293: 1048–1062.
Millan MJ, Lejeune F, Gobert A (2000a). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114–138.
Misu Y, Goshima Y, Ueda H, Kubo T (1985). Presynaptic inhibitory dopamine receptors on noradrenergic nerve terminals: analysis of biphasic actions of dopamine and apomorphine on the release of endogenous norepinephrine in rat hypothalamic slices. J Pharmacol Exp Ther 235: 771–777.
Muscat R, Papp M, Willner P (1992). Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 31: 937–946.
Parini S, Renoldi G, Battaglia A, Invernizzi RW (2005). Chronic reboxetine desensitizes terminal but not somatodendritic alpha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology 30: 1048–1055.
Piercey MF (1998). Pharmacology of pramopexole, a dopamine D3 preferring agonist useful in treating Parkinson disease. Clin Neuropharmacol 21: 141–151.
Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996). Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312: 35–44.
Piercey MF, Smith MW, Lum-Ragan JT (1994). Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther 268: 1297–1303.
Pineyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51: 533–591.
Pitts DK, Wang L, Kelland MD, Freeman AS, Chiodo LA (1995). Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole. J Pharmacol Exp Ther 275: 412–421.
Reichmann H, Odin P, Brecht HM, Koster J, Kraus PH (2006). Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole. J Neural Transm (Suppl. 71): 17–25.
Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS et al (2000). Pramipexole augmentation in treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 12: 137–140.
Subramaniam S, Lucki I, McGonigle P (1992). Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res 571: 313–322.
Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G (1998). D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779: 58–74.
Szabo ST, Blier P (2001). Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 25: 845–857.
Szabo ST, Blier P (2002). Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 302: 983–991.
Tremblay P, Blier P (2006). Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 7: 149–158.
Ungless MA, Magill PJ, Bolam JP (2004). Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303: 2040.
Waehrens J, Gerlach J (1981). Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J Affect Disord 3: 193–202.
Yokoyama C, Okamura H, Nakajima T, Taguchi J, Ibata Y (1994). Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol 344: 121–136.
Acknowledgements
This study was supported by the Canadian Institutes of Health Research grant to PB. We thank Boehringer Ingelheim Pharmaceuticals and Servier Research Institute for kindly providing pramipexole and S 33084, respectively.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chernoloz, O., Mansari, M. & Blier, P. Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain. Neuropsychopharmacol 34, 651–661 (2009). https://doi.org/10.1038/npp.2008.114
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2008.114
Keywords
This article is cited by
-
A clinical guide to rare male sexual disorders
Nature Reviews Urology (2024)
-
The effects of pramipexole on motivational vigour during a saccade task: a placebo-controlled study in healthy adults
Psychopharmacology (2024)
-
Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson’s disease
npj Parkinson's Disease (2021)
-
Impulse control disorders in Parkinson’s disease
Journal of Neural Transmission (2018)
-
Chronic administration of the dopamine D2/3 agonist ropinirole invigorates performance of a rodent slot machine task, potentially indicative of less distractible or compulsive-like gambling behaviour
Psychopharmacology (2017)